Prognostic value of minimal residual disease measured by fusion?gene transcript in infants with <i>KMT2A</i> ?rearranged acute lymphoblastic leukaemia treated according to the MLL?Baby protocol

The prognostic value of minimal residual disease (MRD) measured by fusion-gene transcript (FGT) detection was investigated in 76 infants (aged ?1 year) with acute lymphoblastic leukaemia (ALL) lysine methyltransferase 2A (KMT2A) rearrangements. Either at the end induction or later time-points, FGT-MRD-positivity associated poor outcome. after first consolidation high-risk block detected 46·5% extremely outcome [disease-free survival (SE) 0·06 (0·06), cumulative incidence relapse 0·91 (0·05)], which also confirmed multivariable analysis. Thus, FGT-MRD measurement a single time-point clearly identifies ALL who are curable conventional chemotherapy and those would benefit only from other treatment approaches.